Screens using RNAi and cDNA expression as surrogates for genetics in mammalian tissue culture cells

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 449-459

  Pearlberg, J ^a   Degot, S ^a   Endege, W ^a   Park, J ^a   Davies, J ^a   Gelfand, E ^a   Sawyer, J ^a   Conery, A ^a   Doench, J ^a   Li, W ^a   Gonzalez, L ^a   Boyce, F M ^a   Brizuela, L ^a   LaBaer, J ^a   Grueneberg, D ^a   Harlow, E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BLASTICIDIN; BLASTICIDIN S; CARBOHYDRATE; CELL PROTEIN; COMPLEMENTARY DNA; HYGROMYCIN; LIPID; NEOMYCIN; NUCLEOTIDE; PHOSPHOTRANSFERASE; PROTEOME; PUROMYCIN; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; PLASMID DNA;

BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; CULTURE TECHNIQUE; DISEASE MARKER; DNA MODIFICATION; DNA TRANSFECTION; ENZYME ANALYSIS; FEASIBILITY STUDY; FUNGAL GENE; GENE INTERACTION; GENE REPRESSION; GENETIC EPISTASIS; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN GENOME; LUNG CANCER; MOLECULAR CLONING; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TISSUE CULTURE CELL; ARTICLE; CELL PROLIFERATION; CYTOMEGALOVIRUS; GENE MUTATION; LENTIVIRINAE; LONG TERMINAL REPEAT; MOLONEY MURINE LEUKEMIA VIRUS; NEOPLASM; OPEN READING FRAME; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEOMICS; RNAI THERAPEUTICS; VIRUS INFECTION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELLS, CULTURED; DNA, COMPLEMENTARY; GENE EXPRESSION; GENETIC SCREENING; GENOMICS; HUMANS; LUNG NEOPLASMS; PHENOTYPE; PHOSPHOTRANSFERASES; RETROVIRIDAE; RNA INTERFERENCE; SUPPRESSION, GENETIC; TRANSFECTION;

MAMMALIA;

EID: 33746454623     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.047     Document Type: Conference Paper

References (30)

1. Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S., Markowitz S., Willson J.K., Parmigiani G., Kinzler K.W., Vogelstein B., and Velculescu V.E. 2003. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300: 949.
2. Brizuela L., Richardson A., Marsischky G., and LaBaer J. 2002. The FLEXGene repository: Exploiting the fruits of the genome projects by creating a needed resource to face the challenges of the post-genomic era. Arch. Med. Res. 33: 318.
3. Brummelkamp T.R., Bernards R., and Agami R. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550.
4. Carpenter A.E. and Sabatini D.M. 2004. Systematic genome-wide screens of gene function. Nat. Rev. Genet. 5: 11.
5. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., and Shepard H.M. 1992. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. 89: 4285.
6. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., and Slamon D.J. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17: 2639.
7. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., and Van Cutsem E. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351: 337.
8. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., and Hooper S., et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417: 949.
9. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031.
10. Forsburg S.L. 2001. The art and design of genetic screens: Yeast. Nat. Rev. Genet. 2: 659.
11. Hafen E., Basler K., Edstroem J.E., and Rubin G.M. 1987. Sevenless, a cell-specific homeotic gene of Drosophila, encodes a putative transmembrane receptor with a tyrosine kinase domain. Science 236: 55.
12. Hannon G.J. 2002. RNA interference. Nature 418: 244.
13. Hannon G.J. and Rossi J.J. 2004. Unlocking the potential of the human genome with RNA interference. Nature 431: 371.
14. Hartwell L.H., Culotti J., and Reid B. 1970. Genetic control of the cell-division cycle in yeast. I. Detection of mutants. Proc. Natl. Acad. Sci. 66: 352.
15. Hartwell L.H., Culotti J., Pringle J.R., and Reid B.J. 1974. Genetic control of the cell division cycle in yeast. Science 183: 46.
16. Hunter T. 2000. Signaling - 2000 and beyond. Cell 100: 113.
17. Inoue H., H. Nojima, and H. Okayama. 1990. High efficiency transformation of Escherichia coli with plasmids. Gene 96: 23.
18. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., and Weinberg R.A. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4: 1.
19. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A.. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350: 2129.
20. Moffat J. and Sabatini D.M. 2006. Building mammalian signalling pathways with RNAi screens. Nat. Rev. Mol. Cell Biol. 7: 177.
21. Moffat J. Grueneberg D.A., Yang X., Kim S.Y., Kloepfer A.M., Hinkle G., Piqani B., Eisenhaure T.M., Luo B., Grenier J.K., Carpenter A.E., Foo S.Y., Stewart S.A., Stockwell B.R., Hacohen N., Hahn W.C. Lander E.S., Sabatini D.M., and Root D.E. 2006. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124: 1283.
22. Moon R.T., Kohn A.D., De Ferrari G.V., and Kaykas A.. 2004. WNT and beta-catenin signalling: Diseases and therapies. Nat. Rev. Genet. 5: 691.
23. Nurse P., Masui Y., and Hartwell L.. 1998. Understanding the cell cycle. Nat. Med. 4: 1103.
24. Paddison P.J., Caudy A.A., Sachidanandam R., and Hannon G.J. 2004. Short hairpin activated gene silencing in mammalian cells. Methods Mol. Biol. 265: 85.
25. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M.. 2004. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497.
26. Park J., Hu Y., Murthy T.V., F. Vannberg, Shen B., Rolfs A., Hutti J.E., Cantley L.C., LaBaer J., E. Harlow, and L. Brizuela. 2005. Building a human kinase gene repository: Bioinformatics, molecular cloning, and functional validation. Proc. Natl. Acad. Sci. 102: 8114.
27. Pearlberg J. and LaBaer J. 2004. Protein expression clone repositories for functional proteomics. Curr. Opin. Chem. Biol. 8: 98.
28. Rual J.F., Hirozane-Kishikawa T., Hao T., Bertin N., Li S., Dricot A., Li N., Rosenberg J., Lamesch P., Vidalain P.O., Clingingsmith T.R., Hartley J.L., Esposito D., Cheo D., Moore T., Simmons B., Sequerra R., Bosak S., Doucette-Stamm L., Le Peuch C., Vandenhaute J., Cusick M.E., Albala J.S., Hill D.E., and Vidal M. 2004. Human ORFeome version 1.1: A platform for reverse proteomics. Genome Res. 14: 2128.
29. Simon M.A., Bowtell D.D., Dodson G.S., Laverty T.R., and Rubin G.M. 1991. Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. Cell 67: 701.
30. Xie K. and Abbruzzese J.L. 2003. Developmental biology informs cancer: The emerging role of the hedgehog signaling pathway in upper gastrointestinal cancers. Cancer Cell 4: 245.